|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles |
| Abstract |
|---|
|
|
|---|
Key Words: psoriasis immunosuppression T lymphocyte apoptosis ultraviolet light
Abbreviations used: AnV, Annexin V; APC, allophycocyanin; BB, broad band; FSC, forward scatter; NB, narrow band; PerCP, peridinine chlorophyll protein; PI, propidium iodide; SSC, side scatter; TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling.
Psoriasis vulgaris is a chronic inflammatory skin disease characterized by infiltration of T cells and hyperproliferation of keratinocytes in focal skin areas. In clinical studies, disease-related pathology is reversed by lymphocyte-targeted drugs (1–6), whereas in xenotransplant systems, psoriasis is induced or sustained by intradermal injection of activated T cells (7, 8). Therefore, psoriasis is mediated by activated T cells. In the xenotransplant model, an epidermal hyperplasia response appears to arise from cytokines derived from T cells infiltrating into skin (7). These T cells are probably reacting to a cutaneous antigen, as clonal CD8+ T cell populations have been identified (9) and as systemic administration of the costimulation blocker, CTLA4Ig, reverses clinical and pathological disease features (6). Hence, skin infiltration by activated cutaneous lymphocyte–associated antigen–positive T cells appears to cause a complex inflammatory tissue phenotype that includes (a) the presence of several types of activated leukocytes in skin lesions—CD4+ and CD8+ T cells, neutrophils, and dendritic antigen presenting cells, (b) a diverse array of cytokines produced by activated leukocytes and keratinocytes, (c) proliferation of small blood vessels and epidermal keratinocytes, and (d) increased expression of leukocyte-trafficking adhesion molecules, e.g., intercellular adhesion molecule 1 (ICAM-1), P-selectin, E-selectin, by hyperproliferative endothelial cells or keratinocytes (10).
Ultraviolet B light (UVB, 290–320 nm) is used as a therapeutic modality for psoriasis and other inflammatory skin disorders. Recently, a new UVB source which emits mostly 311/312-nm light (narrow band [NB]-UVB)1 has been introduced for treatment of psoriasis and other inflammatory dermatoses (11–14). UVB irradiation in a variety of animal and human model systems inhibits cutaneous delayed-type hypersensitivity responses to haptens (15, 16), and its therapeutic mechanism in psoriasis has been attributed to these immunosuppressive properties. Interestingly, irradiation of psoriatic skin lesions with standard UVB light causes rapid depletion of intraepidermal T cells (17) and induction of Fas ligand on keratinocytes (18). As apoptosis is induced by in vitro UVB irradiation of T cells, or by incubation of T cells with keratinocytes expressing UVB- induced Fas ligand, it has been proposed that UVB may have immunosuppressive effects in psoriasis through induction of apoptosis in disease-mediating T cells (17, 18). Although cytotoxic effects of UVB on lymphocytes in vivo are unproven, irradiation of atopic dermatitis skin lesions with high-dose UVA (the delivered dose is
NB-UVB Treatment.
Histopathological Analysis.
Psoriatic Epidermal Cell Suspensions.
NB-UVB Irradiation In Vitro.
Flow Cytometric Detection of T Cell Apoptosis.
Flow Cytometric Phenotyping of T Cells in Psoriatic Lesions.
1,000-fold higher than for therapeutic UVB) has produced detectable apoptosis in dermal lymphocytes (19). We now report that 311/ 312-nm UVB is directly cytotoxic for T cells in vivo in psoriatic skin lesions. Furthermore, this new UVB source depletes T cells to a greater extent than broad-band (BB)- UVB from both epidermis and dermis of affected skin.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Reagents.
The following antibodies were used by FACSCalibur® analysis (Becton Dickinson): peridinine chlorophyll protein (PerCP)– or allophycocyanin (APC)–anti-CD3, PE–anti-CD4, FITC–anti-CD8 (Becton Dickinson), and isotype mouse IgG mAbs.
23 adult patients (16 men and 7 women) received irradiation with NB-UVB (312 nm, Philips TL01) on one vertical half of the body and BB-UVB (290–320 nm, FST72T12) on the other vertical half. Five additional patients received NB-UVB on the whole body. The minimum erythema dose for each patient was established before irradiation. On each subsequent day, NB- and BB-UVB irradiations were increased by 15% unless marked erythema developed. Treatment was terminated upon attaining clinical resolution of psoriatic lesions, typically after 4–5 wk of daily treatment (20).
Skin punch biopsies were taken from psoriatic lesions of both NB- and BB-UVB–treated sites before and after UVB treatment. Biopsies were frozen in OCT solution (Miles Diagnostic Division) for histological analysis. Unconjugated anti-CD3 mAb was applied to cryosections for 60 min at room temperature. After washing with PBS, bound antibody was visualized by the avidin-biotin complex detection system (Vectastain ABC; Vector Laboratories, Inc.) with 3-amino-9-ethylcarbazol as the chromagen. For double staining, alkaline phosphatase substrate (Vector Laboratories, Inc.) was also used. Number of CD3+ cells was counted on the image analyzer using NIH image public domain software. Detection of apoptosis in tissue sections was performed by the TUNEL (TdT-mediated dUTP-biotin nick end labeling) reaction as described (17). TdT (Amersham Pharmacia Biotech) and biotin-16-dUTP (Boehringer Mannheim) are used for this technique.
The shave biopsies were taken from eleven patients immediately before the start of treatment and after 1 and 2 wk of treatment with NB-UVB. The tissue was washed twice with sterile PBS, incubated in PBS with 1 mg/ml gentamicin (Life Technologies) for 1 h at 4°C, washed twice in PBS, and floated in 0.5% dispase (Sigma Chemical Co.) overnight at 4°C. The epidermis was removed and teased into a cell suspension after brief trypsinization.
Narrow-band fluorescent UVB lamps (TL01) were used as a light source. PBMCs were prepared from heparinized venous blood of healthy volunteers by Ficoll sedimentation and then irradiated in uncovered tissue culture plates (106 cells/well) in PBS. After irradiation, they were suspended in RPMI 1640 with 5% heat-inactivated normal human serum (C-six Diagnostics, Inc.) with antibiotics.
T cell apoptosis was detected using FITC–Annexin V (AnV) staining in conjunction with a membrane integrity probe (propidium iodide [PI]). In vitro–irradiated PBMCs, or epidermal cell suspensions obtained from NB-UVB–treated psoriatic lesions, were stained with APC–anti-CD3 mAb and FITC–AnV (Kamiya Biomedical Co.). After washing, the cells were stained with PI, and fluorescence intensity was measured by a four-color FACSCalibur®.
Psoriatic epidermal cell suspensions were stained with selected mAbs. After washing with PBS/0.1% sodium azide/2% FBS, cells were fixed with PBS/3.75% formaldehyde and analyzed by flow cytometry within 1 wk. Flow cytometric analysis was done using CellQuest software (Becton Dickinson).
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
NB-UVB Depletes T Cells From Psoriatic Lesions More than BB-UVB.
Psoriatic plaques in 23 patients were treated daily with NB-UVB or BB-UVB in a bilateral comparison study (20). The ability of NB-UVB or BB-UVB to deplete T cells from psoriatic lesions was studied with CD3 antibodies and quantitative image analysis using immunohistochemistry (Fig. 1 A). Both forms of UVB reduced intraepidermal T cells from lesional skin, but quantitative reductions were greater with NB-UVB (96 vs. 85% reduction, P = 0.01; Fig. 1 B). Reductions in dermal CD3+ cells were also greater with NB-UVB (54 vs. 29% reduction, P < 0.01; Fig. 1, A and B). Flow cytometric analysis confirmed that rapid decreases in the number of CD3+, CD4+, and CD8+ T cell subsets in psoriatic epidermis occur during the first 2 wk of treatment (Fig. 1 C).
|
|
|
|
| Discussion |
|---|
|
|
|---|
Surprisingly, immune-modulating effects of 311–312-nm UVB have not been studied previously in psoriatic skin or skin lesions of other inflammatory diseases. The results of this study show that NB-UVB causes greater depletion of T cells in psoriatic tissue than BB-UVB, and establish direct cytotoxic actions of UVB on T cells infiltrating skin lesions. The in vivo results are paralleled by in vitro experiments where exposure of T cells to moderate doses of 312-nm UVB light induced rapid apoptosis. In fact, given that
10% of UVB energy incident on skin penetrates the epidermis, there is reasonably good agreement between doses of 312-nm UVB required to kill T cells (50–100 mJ/cm2) and therapeutic amounts of 312-nm UVB delivered to psoriatic lesions (300–1,200 mJ/cm2). The greater effectiveness of 312-nm UVB in depletion of dermal T cells is probably related to (a) somewhat deeper penetration of this wavelength in dermis compared with the composite of wavelengths present in BB-UVB sources (30, 31), and (b) the ability to deliver more Joules of UVB energy with NB-UVB sources due to a reduction in its burning potential.
These investigations do not define biochemical pathways mediating the cytotoxic or immunosuppressive effects of NB-UVB. Previous studies with BB-UVB have suggested that apoptosis of epidermal T cells might be induced by interaction of Fas on T cells and upregulated Fas ligand on irradiated keratinocytes (18). Although this mechanism could also pertain to 312-nm UVB, rapid apoptosis was produced in isolated leukocytes by direct irradiation in vitro with relatively small amounts of UVB (17, 32). Potential molecular targets of UVB in T cells include p53, which is upregulated or stabilized after UVB exposure in some cells and can potentially mediate apoptosis in the setting of UVB-induced DNA damage (33, 34), or calmodulin-dependent protein kinase II, which is activated after UVB exposure and leads to activation of AP24, 24-kD apoptotic protease (35, 36). In addition, low-dose UVB can inactivate signal transducer and activator of transcription 1 (STAT-1), a critical component of signal transduction, which then inhibits gene transcription (37, 38).
In most cases, direct irradiation of normal skin with erythemogenic amounts of UVB prevents delayed-type hypersensitivity reactions to topical sensitizers. This altered immune reactivity has been attributed to UVB-induced depletion of Langerhans cells from epidermis (39). In a prior study, therapeutic amounts of BB-UVB did not appreciably reduce the abundance of CD1a+ epidermal cells in lesional psoriatic skin (17). We detected no obvious reductions in CD1a+ cells after irradiation of psoriatic lesions with NB-UVB (data not shown). Hence, depletion of T cells from psoriatic lesions appears to be selective for a restricted set of leukocytes. Accordingly, our studies suggest that the major therapeutic mechanism of UVB light in inflammatory dermatoses is a cytotoxic effect on skin-infiltrating T cells, where the mechanism of death is most likely through apoptosis.
| Acknowledgments |
|---|
Submitted: 15 September 1998
Revised: 11 December 1998
| References |
|---|
|
|
|---|
1 Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P & Revillard JP. CD4 antibody treatment of severe psoriasis, Lancet, 1991, 338, 321, .[Medline]
2 Weinshenker BG, Bass BH, Ebers GC & Rice GPA. Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment, J Am Acad Dermatol, 1989, 20, 1132–1133.[Medline]
3 Cooper KD, Baadsgaard O, Ellis CN, Duell E & Voorhees JJ. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis, J Investig Dermatol, 1990, 94, 649–656.[Medline]
4 Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM et al.. Cyclosporine improves psoriasis in a double-blind study, JAMA (J Am Med Assoc), 1986, 256, 3110–3116.
5 Kanerva L, Lauharanta J, Niemi K-M & Lassus A. Light and electron microscopy of psoriatic skin before and during retinoid (Ro 10-9359) and retinoid-PUVA treatment, J Cutan Pathol, 1982, 9, 175–188.[Medline]
6 Krueger JG, Hayes E, Brown M, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Hecker DJ, Mann RM & Abrams JR. Blockade of T-cell costimulation with CTLA4Ig (BMS-188667) reverses pathologic inflammation and keratinocyte activation in psoriatic plaques, J Investig Dermatol, 1997, 108, 555, . (Abstr.).
7 Wrone-Smith T & Nickoloff BJ. Dermal injection of immunocytes induces psoriasis, J Clin Invest, 1996, 98, 1878–1887.[Medline]
8 Gilhar A, David M, Ullmann R, Berkutski T & Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice, J Investig Dermatol, 1997, 109, 283–288.[Medline]
9 Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ & Brostoff SW. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes, Proc Natl Acad Sci USA, 1994, 91, 9282–9286.
10 Nickoloff BJ. The cytokine network in psoriasis, Arch Dermatol, 1991, 127, 871–881.
11 van Weelden H, Baart de la Faille H, Young E & van der Leun JC. A new development in UVB phototherapy of psoriasis, Br J Dermatol, 1988, 119, 11–19.[Medline]
12 Green C, Ferguson J, Lakshmipathi T & Johnson BE. 311 nm UVB phototherapy—an effective treatment for psoriasis, Br J Dermatol, 1988, 119, 691–696.[Medline]
13 Green C, Lakshmipathi T, Johnson BE & Ferguson J. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients, Br J Dermatol, 1992, 127, 5–9.[Medline]
14 Guckian M, Jones CD, Vestey JP, Cooper EJ, Dawe R, Gibbs NK & Norval M. Immunomodulation at the initiation of phototherapy and photochemotherapy, Photodermatol Photoimmunol Photomed, 1995, 11, 163–169.[Medline]
15 Cooper KD. Cell-mediated immunosuppressive mechanisms induced by UV radiation, Photochem Photobiol, 1996, 63, 400–406.[Medline]
16 Simon JC, Krutmann J, Elmets CA, Bergstresser PR & Cruz PD Jr. Ultraviolet B-irradiated antigen-presenting cells display altered accessory signaling for T-cell activation: relevance to immune responses initiated in skin, J Investig Dermatol, 1992, 98, 66S–69S.[Medline]
17 Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, Austin LM & Gottlieb AB. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells, J Exp Med, 1995, 182, 2057–2068.
18 Gutierrez-Steil C, Wrone-Smith T, Sun X, Krueger JG, Coven T & Nickoloff BJ. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B–irradiated psoriatic plaques express Fas ligand (CD95L), J Clin Invest, 1998, 101, 33–39.[Medline]
19 Morita A, Werfel T, Stege H, Ahrens C, Karmann K, Grewe M, Grether-Beck S, Ruzicka T, Kapp A, Klotz L-O et al.. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy, J Exp Med, 1997, 186, 1763–1768.
20 Coven TR, Burack LH, Gilleaudeau P, Keogh M, Ozawa M & Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B, Arch Dermatol, 1997, 133, 1514–1522.
21 Wrone-Smith T, Mitra RS, Thompson CB, Jasty R, Castle VP & Nickoloff BJ. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin, Am J Pathol, 1997, 151, 1321–1329.[Abstract]
22 Yoo EK, Rook AH, Elenitsas R, Gasparro FP & Vowels BR. Apoptosis induction by ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action, J Investig Dermatol, 1996, 107, 235–242.[Medline]
23 Parrish JA & Jaenicke KF. Action spectrum for phototherapy of psoriasis, J Investig Dermatol, 1981, 76, 359–362.[Medline]
24 El-Ghorr A & Norval M. Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review, J Photochem Photobiol B, 1997, 38, 99–106.[Medline]
25 Kang K, Hammerberg C, Meunier L & Cooper KD. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein, J Immunol, 1994, 153, 5256–5264.[Abstract]
26 Rivas JM & Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte- derived IL-10, J Immunol, 1992, 149, 3865–3871.[Abstract]
27 Ullrich SE. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation. Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells, J Immunol, 1994, 152, 3410–3416.[Abstract]
28 Nishigori C, Yarosh DB, Ullrich SE, Vink AA, Bucana CD, Roza L & Kripke ML. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes, Proc Natl Acad Sci USA, 1996, 93, 10354–10359.
29 Rattis F-M, Peguet-Navarro J, Courtellemont P, Redziniak G & Schmitt D. In vitroeffects of ultraviolet B radiation on human Langerhans cell antigen-presenting function, Cell Immunol, 1995, 164, 65–72.[Medline]
30 Everett MA, Yeargers E, Sayre RM & Olson RL. Penetration of epidermis by ultraviolet rays, Photochem Photobiol, 1966, 5, 533–542.[Medline]
31 Bruls WAG, Slaper H, van der Leun JC & Berrens L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths, Photochem Photobiol, 1984, 40, 485–494.[Medline]
32 Yaron I, Yaron R, Oluwole SF & Hardy MA. UVB irradiation of human-derived peripheral blood lymphocytes induces apoptosis but not T-cell anergy: additive effects with various immunosuppressive agents, Cell Immunol, 1996, 168, 258–266.[Medline]
33 Schwartz SM & Bennett MR. Death by any other name, Am J Pathol, 1995, 147, 229–234.[Medline]
34 Cotton J & Spandau DF. Ultraviolet B-radiation dose influences the induction of apoptosis and p53 in human keratinocytes, Radiat Res, 1997, 147, 148–155.[Medline]
35 Wright SC, Wei QS, Kinder DH & Larrick JW. Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide–deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation, J Exp Med, 1996, 183, 463–471.
36 Wright SC, Schellenberger U, Ji L, Wang H & Larrick JW. Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis, FASEB J, 1997, 11, 843–849.[Abstract]
37 Aragane Y, Kulms D, Luger TA & Schwarz T. Down-regulation of interferon
-activated STAT1 by UV light, Proc Natl Acad Sci USA, 1997, 94, 11490–11495.
38 Aragane Y, Schwarz A, Luger TA, Ariizumi K, Takashima A & Schwarz T. Ultraviolet light suppresses IFN-
-induced IL-7 gene expression in murine keratinocytes by interfering with IFN regulatory factors, J Immunol, 1997, 158, 5393–5399.[Abstract]
39 Murphy GM, Norris PG, Young AR, Corbett MF & Hawk JLM. Low-dose ultraviolet-B irradiation depletes human epidermal Langerhans cells, Br J Dermatol, 1993, 129, 674–677.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|